Haloperidol decanoate patient information

Haloperidol is a typical butyrophenone type antipsychotic that exhibits high affinity dopamine D 2 receptor antagonism and slow receptor dissociation kinetics. [42] It has effects similar to the phenothiazines . [17] The drug binds preferentially to D 2 and α 1 receptors at low dose (ED 50 = and  mg/kg, respectively), and 5-HT 2 receptors at a higher dose (ED 50 =  mg/kg). Given that antagonism of D 2 receptors is more beneficial on the positive symptoms of schizophrenia and antagonism of 5-HT 2 receptors on the negative symptoms, this characteristic underlies haloperidol's greater effect on delusions, hallucinations and other manifestations of psychosis. [43] Haloperidol's negligible affinity for histamine H 1 receptors and muscarinic M 1 acetylcholine receptors yields an antipsychotic with a lower incidence of sedation, weight gain, and orthostatic hypotension though having higher rates of treatment emergent extrapyramidal symptoms .

Call your doctor right away if you notice any of these side effects:

  • Allergic reaction: Itching or hives, swelling in your face or hands, swelling or tingling in your mouth or throat, chest tightness, trouble breathing
  • Blood in your urine.
  • Chills, sore throat, and body aches.
  • Decreased thirst.
  • Fast or uneven heartbeat.
  • Feeling very thirsty or hungry.
  • Fever, sweating, confusion, or muscle stiffness.
  • Lightheadedness or fainting.
  • Problems with vision, speech, balance, or walking.
  • Seeing or hearing things which are not there.
  • Seizures (convulsions).
  • Tremors or movements that you cannot control in the tongue, face, neck, jaw, or eyes
  • Trouble breathing or swallowing.
  • Trouble with swallowing or talking, sticking out of the tongue, or spasm of the neck muscles.
  • Unusual bleeding, bruising, or weakness.
  • Unusual facial expressions.
  • Yellowing of your skin or the whites of your eyes.
If you notice these less serious side effects, talk with your doctor:
  • Anxiety, drowsiness, or depression.
  • Decrease in how much or how often you urinate.
  • Dry mouth, cough, or headache.
  • Hair loss.
  • Loss of appetite.
  • Nausea, vomiting, diarrhea, or stomach upset.
  • Pain in the breast, irregular menstrual periods.
  • Skin rash, soreness, or pain at the injection site.
  • Trouble having sex or increased development of breasts (in men).
  • Trouble sleeping or restlessness.

This information should not be used to decide whether or not to take haloperidol decanoate injection or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to haloperidol decanoate injection. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

The influence of renal impairment on the pharmacokinetics of haloperidol has not been evaluated. About one-third of a haloperidol dose is excreted in urine, mostly as metabolites. Less than 3% of administered haloperidol is eliminated unchanged in the urine. Haloperidol metabolites are not considered to make a significant contribution to its activity, although for the reduced metabolite of haloperidol, back-conversion to haloperidol cannot be fully ruled out. Even though impairment of renal function is not expected to affect haloperidol elimination to a clinically relevant extent, caution is advised in patients with renal impairment, and especially those with severe impairment, due to the long half-life of haloperidol and its reduced metabolite, and the possibility of accumulation (see section ).

Haloperidol decanoate patient information

haloperidol decanoate patient information

The influence of renal impairment on the pharmacokinetics of haloperidol has not been evaluated. About one-third of a haloperidol dose is excreted in urine, mostly as metabolites. Less than 3% of administered haloperidol is eliminated unchanged in the urine. Haloperidol metabolites are not considered to make a significant contribution to its activity, although for the reduced metabolite of haloperidol, back-conversion to haloperidol cannot be fully ruled out. Even though impairment of renal function is not expected to affect haloperidol elimination to a clinically relevant extent, caution is advised in patients with renal impairment, and especially those with severe impairment, due to the long half-life of haloperidol and its reduced metabolite, and the possibility of accumulation (see section ).

Media:

haloperidol decanoate patient informationhaloperidol decanoate patient informationhaloperidol decanoate patient informationhaloperidol decanoate patient informationhaloperidol decanoate patient information

http://buy-steroids.org